EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

Deepak Almeida iD, Si-Yang Li, Jin Lee, Barry Hafkin, Khisimuzi Mdluli, Nader Fotouhi, Eric L Nuermberger iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00789-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Deepak Almeida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Oxazolidinones, Tuberculosis, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Alliance for Tuberculosis Drug Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Contezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mouse model of tuberculosis. Contezolid had an MIC of 1 µg/mL, similar to linezolid, and exhibited similar bactericidal activity in mice. Contezolid-resistant mutants selected in vitro had 32- to 64-fold increases in contezolid MIC and harbored mutations in the mce3R gene. These mutants did not display cross-resistance to linezolid. Our results indicate that contezolid has the potential to replace linezolid in regimens containing bedaquiline and pretomanid and likely other regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxazolidinonesTuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAnimalsMiceLinezolidAntitubercular AgentsDisease Models, AnimalDiarylquinolinesPyridonesNitroimidazoles

Stichwörter der Autor:innen

Mycobacterium tuberculosiscontezolidoxazolidinones

Substanzen

LinezolidAntitubercular AgentsOxazolidinonesDiarylquinolinescontezolidPyridonesbedaquilinepretomanidNitroimidazoles

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA.
  • MicuRx Pharmaceuticals, Foster City, California, USA.
  • Global Alliance for Tuberculosis Drug Development, New York, USA.

ORCID-Profile: Deepak Almeida, Eric L Nuermberger

Förderung

  • Global Alliance for Tuberculosis Drug Development

Zitieren

APA

Almeida, D., Li, S. Y., Lee, J., Hafkin, B., Mdluli, K., Fotouhi, N., & Nuermberger, E. L. (2023). Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00789-23

Vancouver

Almeida D, Li SY, Lee J, Hafkin B, Mdluli K, Fotouhi N, et al. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00789-23

BibTeX
@article{Almeida2023,
  author = {Almeida, Deepak and Li, Si-Yang and Lee, Jin and Hafkin, Barry and Mdluli, Khisimuzi and Fotouhi, Nader and Nuermberger, Eric L},
  title = {Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00789-23}
}
Kostenlos starten →